Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 46 | 2023 | 15784 | 1.160 |
Why?
|
Ritonavir | 7 | 2018 | 310 | 0.870 |
Why?
|
Anti-HIV Agents | 16 | 2023 | 4081 | 0.850 |
Why?
|
Bone Diseases, Metabolic | 2 | 2021 | 408 | 0.770 |
Why?
|
Nevirapine | 5 | 2016 | 268 | 0.760 |
Why?
|
Antiretroviral Therapy, Highly Active | 15 | 2018 | 1881 | 0.680 |
Why?
|
Horses | 2 | 2016 | 294 | 0.590 |
Why?
|
Bone Density Conservation Agents | 2 | 2021 | 785 | 0.590 |
Why?
|
Receptors, Opioid, mu | 1 | 2016 | 172 | 0.560 |
Why?
|
HIV-1 | 18 | 2018 | 6838 | 0.530 |
Why?
|
AIDS-Related Opportunistic Infections | 5 | 2013 | 658 | 0.530 |
Why?
|
Locomotion | 1 | 2016 | 376 | 0.500 |
Why?
|
Research Design | 4 | 2022 | 5902 | 0.490 |
Why?
|
Fentanyl | 1 | 2016 | 400 | 0.490 |
Why?
|
Infectious Disease Transmission, Vertical | 6 | 2020 | 1323 | 0.420 |
Why?
|
CD4 Lymphocyte Count | 19 | 2018 | 2546 | 0.390 |
Why?
|
HIV Protease Inhibitors | 4 | 2009 | 430 | 0.370 |
Why?
|
Clinical Trials as Topic | 7 | 2015 | 7960 | 0.340 |
Why?
|
Models, Statistical | 4 | 2022 | 5064 | 0.340 |
Why?
|
Body Composition | 3 | 2018 | 2395 | 0.320 |
Why?
|
HIV | 4 | 2020 | 1525 | 0.310 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 487 | 0.300 |
Why?
|
Rotavirus Vaccines | 2 | 2017 | 72 | 0.290 |
Why?
|
Anti-Retroviral Agents | 4 | 2023 | 1623 | 0.290 |
Why?
|
Animal Technicians | 1 | 2005 | 8 | 0.290 |
Why?
|
Rotavirus Infections | 2 | 2017 | 95 | 0.290 |
Why?
|
Bone Density | 5 | 2021 | 3418 | 0.280 |
Why?
|
Cat Diseases | 1 | 2005 | 38 | 0.280 |
Why?
|
Cross-Over Studies | 4 | 2021 | 2015 | 0.270 |
Why?
|
Dog Diseases | 1 | 2005 | 135 | 0.260 |
Why?
|
Drug Utilization Review | 1 | 2005 | 259 | 0.250 |
Why?
|
RNA, Viral | 10 | 2012 | 2838 | 0.250 |
Why?
|
Zidovudine | 4 | 2012 | 605 | 0.240 |
Why?
|
Child Development | 3 | 2007 | 2199 | 0.230 |
Why?
|
Alendronate | 2 | 2021 | 174 | 0.230 |
Why?
|
Data Interpretation, Statistical | 4 | 2022 | 2729 | 0.230 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1990 | 0.230 |
Why?
|
Analgesics, Opioid | 2 | 2016 | 3409 | 0.230 |
Why?
|
Patient Compliance | 6 | 2009 | 2744 | 0.210 |
Why?
|
Electronics | 1 | 2023 | 291 | 0.210 |
Why?
|
Papillomavirus Infections | 1 | 2013 | 1513 | 0.210 |
Why?
|
Poverty | 1 | 2013 | 2620 | 0.210 |
Why?
|
Acquired Immunodeficiency Syndrome | 5 | 2004 | 2150 | 0.210 |
Why?
|
Child | 33 | 2022 | 74468 | 0.190 |
Why?
|
Adolescent | 32 | 2023 | 85155 | 0.190 |
Why?
|
Psychological Techniques | 1 | 1999 | 48 | 0.180 |
Why?
|
Lamivudine | 2 | 2012 | 336 | 0.170 |
Why?
|
Dideoxynucleosides | 2 | 2009 | 116 | 0.170 |
Why?
|
Analgesics | 1 | 2005 | 1022 | 0.170 |
Why?
|
Blood Glucose | 2 | 2012 | 6259 | 0.160 |
Why?
|
Infant | 22 | 2018 | 34569 | 0.160 |
Why?
|
Mental Competency | 1 | 1999 | 173 | 0.160 |
Why?
|
Child, Preschool | 23 | 2021 | 41198 | 0.160 |
Why?
|
Child Advocacy | 1 | 1996 | 49 | 0.150 |
Why?
|
Dapsone | 3 | 2001 | 64 | 0.140 |
Why?
|
Patient Dropouts | 1 | 1998 | 425 | 0.140 |
Why?
|
Drug Evaluation | 1 | 1996 | 661 | 0.130 |
Why?
|
Prejudice | 2 | 2010 | 574 | 0.130 |
Why?
|
Viral Load | 11 | 2018 | 3254 | 0.130 |
Why?
|
Carcinogenicity Tests | 1 | 1994 | 42 | 0.130 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2013 | 41 | 0.130 |
Why?
|
Horse Diseases | 1 | 2014 | 52 | 0.130 |
Why?
|
Growth | 3 | 2009 | 395 | 0.120 |
Why?
|
Fluconazole | 1 | 2014 | 151 | 0.120 |
Why?
|
Puberty | 2 | 2010 | 462 | 0.120 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1998 | 664 | 0.120 |
Why?
|
Dogs | 2 | 2011 | 4046 | 0.120 |
Why?
|
Anesthesia Recovery Period | 1 | 2014 | 161 | 0.120 |
Why?
|
Female | 50 | 2021 | 377204 | 0.120 |
Why?
|
Humans | 62 | 2023 | 715777 | 0.120 |
Why?
|
Consensus | 1 | 2022 | 2743 | 0.120 |
Why?
|
Male | 48 | 2021 | 350324 | 0.110 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2013 | 193 | 0.110 |
Why?
|
Anesthetics, General | 1 | 2014 | 148 | 0.110 |
Why?
|
Ethics, Research | 1 | 2013 | 179 | 0.110 |
Why?
|
Metabolome | 1 | 2018 | 871 | 0.110 |
Why?
|
Africa South of the Sahara | 1 | 2014 | 708 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2016 | 2292 | 0.100 |
Why?
|
Medication Adherence | 1 | 2023 | 2046 | 0.100 |
Why?
|
Research Subjects | 1 | 2013 | 248 | 0.100 |
Why?
|
Safety | 1 | 1996 | 1217 | 0.100 |
Why?
|
HIV Seropositivity | 4 | 2007 | 914 | 0.100 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2011 | 194 | 0.100 |
Why?
|
Homosexuality | 2 | 2010 | 270 | 0.100 |
Why?
|
Weight Gain | 1 | 2000 | 2221 | 0.100 |
Why?
|
Pain | 1 | 2005 | 4697 | 0.100 |
Why?
|
Age Factors | 8 | 2009 | 18784 | 0.090 |
Why?
|
Splenectomy | 1 | 2011 | 406 | 0.090 |
Why?
|
Cross-Sectional Studies | 9 | 2020 | 23438 | 0.090 |
Why?
|
Stavudine | 2 | 1999 | 86 | 0.090 |
Why?
|
Bisexuality | 2 | 2010 | 282 | 0.090 |
Why?
|
Absorptiometry, Photon | 2 | 2012 | 1709 | 0.090 |
Why?
|
Eye Diseases | 1 | 2014 | 653 | 0.090 |
Why?
|
Immunoglobulin A | 3 | 2017 | 969 | 0.080 |
Why?
|
India | 1 | 2014 | 2060 | 0.080 |
Why?
|
Cognition | 2 | 2007 | 6077 | 0.080 |
Why?
|
Analgesia, Epidural | 1 | 2011 | 308 | 0.080 |
Why?
|
Survival Analysis | 2 | 1999 | 10499 | 0.080 |
Why?
|
Bupivacaine | 1 | 2011 | 425 | 0.080 |
Why?
|
Infant, Newborn | 7 | 2015 | 24798 | 0.080 |
Why?
|
Morphine | 1 | 2011 | 637 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 3 | 2010 | 2034 | 0.080 |
Why?
|
Hospitals, Animal | 1 | 2005 | 3 | 0.070 |
Why?
|
HIV Seronegativity | 1 | 2007 | 207 | 0.070 |
Why?
|
Flaviviridae Infections | 1 | 2005 | 8 | 0.070 |
Why?
|
GB virus C | 1 | 2005 | 10 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2018 | 62004 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2006 | 4378 | 0.070 |
Why?
|
Hepatitis, Viral, Human | 1 | 2005 | 133 | 0.070 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2008 | 602 | 0.070 |
Why?
|
Cluster Analysis | 1 | 2012 | 2758 | 0.070 |
Why?
|
Pediatrics | 1 | 2000 | 3552 | 0.060 |
Why?
|
Young Adult | 8 | 2020 | 56226 | 0.060 |
Why?
|
Anti-Infective Agents | 3 | 2001 | 945 | 0.060 |
Why?
|
Anesthetics, Local | 1 | 2011 | 986 | 0.060 |
Why?
|
Pneumonia, Pneumocystis | 3 | 2001 | 246 | 0.060 |
Why?
|
Cats | 1 | 2005 | 1034 | 0.060 |
Why?
|
Movement | 1 | 2011 | 1473 | 0.060 |
Why?
|
Longitudinal Studies | 4 | 2020 | 13643 | 0.060 |
Why?
|
Drug Resistance, Viral | 1 | 2008 | 780 | 0.060 |
Why?
|
Drug Therapy, Combination | 6 | 2012 | 6552 | 0.060 |
Why?
|
Asian Americans | 1 | 2008 | 675 | 0.060 |
Why?
|
Proportional Hazards Models | 4 | 2006 | 12456 | 0.060 |
Why?
|
Spine | 1 | 2010 | 1111 | 0.060 |
Why?
|
Minority Groups | 1 | 2010 | 1088 | 0.060 |
Why?
|
Logistic Models | 3 | 2012 | 13618 | 0.060 |
Why?
|
Double-Blind Method | 5 | 2020 | 11945 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 9596 | 0.050 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2002 | 129 | 0.050 |
Why?
|
Treatment Failure | 3 | 2016 | 2677 | 0.050 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12480 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2006 | 4262 | 0.050 |
Why?
|
Likelihood Functions | 2 | 2002 | 991 | 0.050 |
Why?
|
Drug Administration Schedule | 5 | 2011 | 5031 | 0.050 |
Why?
|
Prenatal Care | 1 | 2008 | 1040 | 0.050 |
Why?
|
Developing Countries | 1 | 2013 | 2737 | 0.050 |
Why?
|
Pain, Postoperative | 1 | 2011 | 1629 | 0.050 |
Why?
|
Time Factors | 7 | 2009 | 40875 | 0.050 |
Why?
|
Hepatitis B Vaccines | 1 | 2000 | 193 | 0.050 |
Why?
|
Didanosine | 1 | 1999 | 146 | 0.050 |
Why?
|
Statistics, Nonparametric | 3 | 2004 | 2950 | 0.040 |
Why?
|
Body Height | 2 | 2005 | 1609 | 0.040 |
Why?
|
Prospective Studies | 7 | 2018 | 51315 | 0.040 |
Why?
|
Cohort Studies | 9 | 2008 | 40029 | 0.040 |
Why?
|
Psychological Tests | 1 | 2000 | 644 | 0.040 |
Why?
|
Viremia | 1 | 2021 | 722 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2010 | 1738 | 0.040 |
Why?
|
Hypercholesterolemia | 1 | 2005 | 1160 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6722 | 0.040 |
Why?
|
Incidence | 2 | 2014 | 20731 | 0.040 |
Why?
|
Antibodies, Neutralizing | 2 | 2017 | 1836 | 0.040 |
Why?
|
Zimbabwe | 1 | 2017 | 127 | 0.040 |
Why?
|
Follow-Up Studies | 9 | 2018 | 39300 | 0.040 |
Why?
|
Models, Biological | 1 | 1994 | 9809 | 0.040 |
Why?
|
Blood Chemical Analysis | 1 | 2018 | 461 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 15603 | 0.040 |
Why?
|
Brazil | 1 | 2020 | 1169 | 0.040 |
Why?
|
Zambia | 1 | 2017 | 250 | 0.040 |
Why?
|
Motor Activity | 1 | 2007 | 2774 | 0.040 |
Why?
|
Virus Shedding | 1 | 2017 | 106 | 0.040 |
Why?
|
Risk-Taking | 3 | 2008 | 995 | 0.040 |
Why?
|
Hepatitis B | 1 | 2000 | 650 | 0.040 |
Why?
|
Vaccines, Attenuated | 1 | 2017 | 330 | 0.040 |
Why?
|
Antibodies, Viral | 2 | 2017 | 2996 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2005 | 1687 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2013 | 19537 | 0.030 |
Why?
|
Africa | 1 | 2017 | 662 | 0.030 |
Why?
|
Animals | 5 | 2016 | 169420 | 0.030 |
Why?
|
Hepatitis C | 1 | 2004 | 1521 | 0.030 |
Why?
|
Body Weight | 2 | 2005 | 4688 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2010 | 4164 | 0.030 |
Why?
|
Sex Distribution | 3 | 2005 | 2371 | 0.030 |
Why?
|
Drug Interactions | 2 | 2014 | 1468 | 0.030 |
Why?
|
Botswana | 1 | 2017 | 980 | 0.030 |
Why?
|
Age Distribution | 3 | 2005 | 2942 | 0.030 |
Why?
|
Premedication | 1 | 2014 | 270 | 0.030 |
Why?
|
Hemophilia A | 3 | 2002 | 352 | 0.030 |
Why?
|
Adult | 16 | 2020 | 212266 | 0.030 |
Why?
|
Tanzania | 1 | 2017 | 1203 | 0.030 |
Why?
|
Critical Illness | 1 | 2005 | 2529 | 0.030 |
Why?
|
Rodentia | 1 | 1994 | 235 | 0.030 |
Why?
|
Immersion | 1 | 1992 | 29 | 0.030 |
Why?
|
Respiratory Muscles | 1 | 1992 | 135 | 0.030 |
Why?
|
Laryngeal Muscles | 1 | 1992 | 93 | 0.030 |
Why?
|
Placebos | 1 | 2017 | 1735 | 0.030 |
Why?
|
Pregnancy | 4 | 2021 | 27398 | 0.030 |
Why?
|
Reference Values | 1 | 1999 | 5050 | 0.030 |
Why?
|
Biodiversity | 1 | 2013 | 350 | 0.030 |
Why?
|
Microwaves | 1 | 1992 | 177 | 0.030 |
Why?
|
Feces | 1 | 2017 | 1378 | 0.020 |
Why?
|
Markov Chains | 1 | 1994 | 985 | 0.020 |
Why?
|
Smoking | 1 | 2008 | 8980 | 0.020 |
Why?
|
Muscle Development | 1 | 1992 | 293 | 0.020 |
Why?
|
South Africa | 1 | 2015 | 1594 | 0.020 |
Why?
|
Area Under Curve | 2 | 2007 | 1687 | 0.020 |
Why?
|
Labor Unions | 1 | 2010 | 57 | 0.020 |
Why?
|
Metabolomics | 1 | 2018 | 1392 | 0.020 |
Why?
|
Leukocyte Count | 1 | 1994 | 1660 | 0.020 |
Why?
|
Confidence Intervals | 1 | 1996 | 2993 | 0.020 |
Why?
|
Aging | 3 | 2003 | 8350 | 0.020 |
Why?
|
Medical History Taking | 1 | 1994 | 801 | 0.020 |
Why?
|
Sex Factors | 2 | 2018 | 10666 | 0.020 |
Why?
|
Algorithms | 3 | 2002 | 13758 | 0.020 |
Why?
|
Drug Monitoring | 1 | 1996 | 939 | 0.020 |
Why?
|
Clinical Competence | 1 | 2005 | 4630 | 0.020 |
Why?
|
Linear Models | 2 | 2010 | 5983 | 0.020 |
Why?
|
Probability | 2 | 2005 | 2487 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2009 | 401 | 0.020 |
Why?
|
United States | 8 | 2008 | 67905 | 0.020 |
Why?
|
Life Expectancy | 1 | 2015 | 1143 | 0.020 |
Why?
|
Vaccination | 1 | 2000 | 2939 | 0.020 |
Why?
|
Plasma | 1 | 1992 | 570 | 0.020 |
Why?
|
Socioeconomic Factors | 3 | 2010 | 7757 | 0.020 |
Why?
|
Tablets | 1 | 2008 | 150 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2010 | 373 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 1994 | 1323 | 0.020 |
Why?
|
Regression Analysis | 3 | 2004 | 6495 | 0.020 |
Why?
|
Heterosexuality | 1 | 2010 | 275 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1581 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2016 | 15909 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 1996 | 1778 | 0.020 |
Why?
|
Carbon Dioxide | 1 | 2011 | 1130 | 0.020 |
Why?
|
Half-Life | 1 | 2007 | 674 | 0.020 |
Why?
|
Patient Selection | 1 | 1998 | 4293 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2009 | 1154 | 0.020 |
Why?
|
Bronchopulmonary Dysplasia | 1 | 1989 | 297 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2010 | 2032 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 1998 | 8890 | 0.020 |
Why?
|
Temperature | 1 | 1992 | 2145 | 0.020 |
Why?
|
Prognosis | 2 | 2009 | 29005 | 0.020 |
Why?
|
CD4-CD8 Ratio | 1 | 2004 | 113 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2006 | 6093 | 0.020 |
Why?
|
Anthropometry | 1 | 2009 | 1370 | 0.020 |
Why?
|
Prevalence | 3 | 2005 | 14911 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2005 | 528 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4902 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5265 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2021 | 72443 | 0.010 |
Why?
|
Drug Combinations | 1 | 2007 | 1928 | 0.010 |
Why?
|
Postpartum Period | 1 | 2008 | 990 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7190 | 0.010 |
Why?
|
Risk Factors | 4 | 2014 | 70866 | 0.010 |
Why?
|
Factor VII | 1 | 2002 | 146 | 0.010 |
Why?
|
Rifabutin | 1 | 2001 | 53 | 0.010 |
Why?
|
Health Care Costs | 1 | 2015 | 3164 | 0.010 |
Why?
|
Administration, Oral | 1 | 2009 | 3956 | 0.010 |
Why?
|
Risk Assessment | 2 | 2018 | 23464 | 0.010 |
Why?
|
Pain Measurement | 1 | 2011 | 3496 | 0.010 |
Why?
|
Antibiotics, Antitubercular | 1 | 2001 | 105 | 0.010 |
Why?
|
Hepatitis B Antibodies | 1 | 2000 | 151 | 0.010 |
Why?
|
Virus Replication | 1 | 2008 | 2565 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 2000 | 375 | 0.010 |
Why?
|
Oxygen | 1 | 2011 | 4162 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2017 | 10284 | 0.010 |
Why?
|
Attitude to Health | 1 | 2008 | 2110 | 0.010 |
Why?
|
Monocytes | 1 | 2007 | 2620 | 0.010 |
Why?
|
Lipids | 1 | 2009 | 3242 | 0.010 |
Why?
|
Breast Neoplasms | 3 | 2002 | 20062 | 0.010 |
Why?
|
Inflammation | 1 | 2017 | 10081 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2008 | 4919 | 0.010 |
Why?
|
Boston | 1 | 2010 | 9377 | 0.010 |
Why?
|
Substance Abuse, Intravenous | 1 | 2000 | 480 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2001 | 1525 | 0.010 |
Why?
|
Health Behavior | 1 | 2008 | 2623 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 6501 | 0.010 |
Why?
|
Phosphorylation | 1 | 2007 | 8658 | 0.010 |
Why?
|
Biometry | 1 | 1999 | 543 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1999 | 1602 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2009 | 3884 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2008 | 18591 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2001 | 15199 | 0.010 |
Why?
|
Neutropenia | 1 | 1998 | 876 | 0.010 |
Why?
|
Disease Progression | 2 | 2001 | 13215 | 0.010 |
Why?
|
Theophylline | 1 | 1992 | 138 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2003 | 2550 | 0.010 |
Why?
|
Clinical Protocols | 1 | 1998 | 1473 | 0.010 |
Why?
|
Calorimetry | 1 | 1992 | 130 | 0.010 |
Why?
|
Bacterial Infections | 1 | 2001 | 1425 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 1998 | 1418 | 0.010 |
Why?
|
Freezing | 1 | 1992 | 297 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2000 | 1923 | 0.010 |
Why?
|
Diaphragm | 1 | 1992 | 329 | 0.010 |
Why?
|
Apnea | 1 | 1992 | 193 | 0.010 |
Why?
|
Odds Ratio | 1 | 2003 | 9984 | 0.010 |
Why?
|
Bronchospirometry | 1 | 1989 | 11 | 0.010 |
Why?
|
Comorbidity | 1 | 2004 | 10435 | 0.010 |
Why?
|
Population Surveillance | 1 | 2000 | 2650 | 0.010 |
Why?
|
Survival Rate | 1 | 2004 | 13206 | 0.010 |
Why?
|
Respiratory Mechanics | 1 | 1992 | 645 | 0.010 |
Why?
|
Risk | 1 | 2001 | 9801 | 0.010 |
Why?
|
Electromyography | 1 | 1992 | 1372 | 0.000 |
Why?
|
Specimen Handling | 1 | 1992 | 698 | 0.000 |
Why?
|
Blood Coagulation | 1 | 1992 | 1110 | 0.000 |
Why?
|
Middle Aged | 2 | 2010 | 214639 | 0.000 |
Why?
|
Infant, Premature | 1 | 1992 | 2032 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2008 | 58323 | 0.000 |
Why?
|
Radiography | 1 | 1989 | 6978 | 0.000 |
Why?
|
Sleep | 1 | 1992 | 4199 | 0.000 |
Why?
|
Aged | 1 | 2008 | 162448 | 0.000 |
Why?
|
Concepts
(299)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(26)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_